** Shares of Divi's Laboratories DIVI.NS fall 4.2% to
4,656 rupees, the most on the Nifty 50 .NSEI
** Novartis NOVN.S loses initial bid to block generic
versions of its top-selling heart drug Entresto, for which
Divi's supplies pharma ingredients, or APIs
** Entresto is among largest drugs in Divi's portfolio and
generics could hurt FY27 EPS by 10%, says Kotak Institutional
Equities
** Adds: "We have not factored in a generic entry in
Entresto, which will hurt earnings, while valuations continue to
stay prohibitively expensive"
** Brokerage reiterates "sell" and a target price of 3,600
rupees, an implied downside of about 26%
** Analysts avg rating on DIVI is "hold"; median target
price is 4,437.50 rupees apiece --LSEG data
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))